Inventor · disambiguated record
Andre Limnander
Also filed as: LIMNANDER ANDRE
3 granted patents·4 pending applications·2 citations·filing 2019–2025
54Inventor score
Files withREGENERON PHARMA7
Top patents by PatentIndex Score
7 records- 0179US11964016B2Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergyREGENERON PHARMA·Filed 2020·Granted Apr 23, 2024·1 cites·99 claims
- 0276US11578127B2Anti-Fc epsilon-R1 alpha (FcεR1α) antibodies, bispecific antigen-binding molecules that bind FcεR1α and CD3, and uses thereofREGENERON PHARMA·Filed 2019·Granted Feb 14, 2023·1 cites·17 claims
- 0373US12441797B2Anti-FC ϵ-R1 α (FCϵR1α) antibodies, bispecific antigen-binding molecules that bind FCϵR1α and CD3, and uses thereofREGENERON PHARMA·Filed 2023·Granted Oct 14, 2025·0 cites·14 claims
- 0471US2024350625A1Combination of il-4/il-13 pathway inhibitors and plasma cell abalation for treating allergyREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0548US2025276092A1Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody responseREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 0647US2025242018A1Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administrationREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 0745US2025242056A1Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosingREGENERON PHARMA·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Andre Limnander files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →